Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$29.43M+13.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yuling Luo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 222
- Beta
- -6.18
- Country
- US
Financials
ALMR has only 2 quarterly periods on file — the charts below show the full history available.
Revenue
$29.43M+13.0%Net Income
$-13.20MEBITDA
$-13.07MFree Cash Flow
$-14.96MEPS (diluted)
$-0.22Shares Outstanding (diluted)
58.67M-15.4%Operating Expenses
$31.25MCash & Debt
$250.05MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $74.21M | $-29.82M | $-0.45 |
Valuation
ALMRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·11d ago·Neutral
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab
View source ↗ - Newsseekingalpha.com·51d ago·Positive
…h Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
…nue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Alamar Biosciences Q2 Earnings Call Highlights Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering.
View source ↗
Earnings
Typical surprise +13.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.22 vs $-0.31beat
- Fri, May 8$-1.74 vs $-1.71miss
Estimates and results for ALMR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALMR officers and directors.
- Bought
- $8.0m
- Sold
- —
2 trades
0 trades
- Illumina Innovation Fund Ii Gp, L.l.c.bought
- Naclerio Nicholasbought
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALMR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.